Mayfair Community Centre in Church Stretton has been named as one of this year’s winners of a GSK IMPACT* Award. From over four hundred charities nationwide who applied to be part of GSK’s flagship UK community investment programme, Mayfair Community Centre is one of only ten winners and stood out due to its community support schemes.
The GSK IMPACT Awards, run in partnership with The King’s Fund and now in their seventeenth year, are seen as a mark of achievement in the healthcare charity sector. In addition to the £30,000 Mayfair will receive in unrestricted funding, they will be able to access training, development, and networking opportunities through a dedicated programme organised by The King’s Fund.
Mayfair will be recognised, along with other award winners, at a ceremony to be held at the Science Museum in London on Thursday 15 May. An overall winner, who will receive a further £10,000 in funding, will also be announced at the ceremony.
Nicola McPherson, Mayfair’s Chief Officer, said: ‘We are delighted to have received national recognition for the work we do here. It is all thanks to the commitment and dedication of our volunteers, trustees and staff and the support we receive from our local community as well as the many organisations we work with, from both the voluntary and public sector. The award gives us a great opportunity to learn from others working within the field as well as the importance of a significant financial award – which will be very helpful to our work’.
Katie Pinnock, Head of UK Charitable Giving at GSK said: ‘Strettons Mayfair Trust plays a very important role in their local area, helping to reduce pressure on NHS services, and connecting people from all areas of the community enabling them to support each other.’
A judging panel of health and charity experts who chose the winners includes broadcast journalist Fiona Phillips; Professor Steve Field, Chief Inspector of Primary Care at the Care Quality Commission; Gilly Green, Head of UK Grants at Comic Relief; Sir Christopher Gent, Chair of GSK, and Sir Chris Kelly, Chair of The King’s Fund.